Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests better way to rebuild jawbone for dental implants

NCT ID NCT07613047

Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two barrier materials used in guided bone regeneration to rebuild the jawbone in areas where teeth are missing. Seventy adults needing horizontal ridge augmentation will be randomly assigned to receive either acellular dermal matrix or a resorbable collagen membrane. The goal is to see which material better restores bone width and improves soft tissue outcomes for future dental implants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acellular dermal matrix (AlloDerm) and resorbable cross-linked collagen membrane
What this could lead to
If successful, this could show that acellular dermal matrix is a better option for rebuilding jawbone width, potentially improving dental implant success.
What could go wrong
This is an early-stage study with only 70 participants, so results may not apply to everyone. The procedure involves surgery with risks like pain, swelling, or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * English speaking * At least 18 years old * Must be a patient of the UAB Dental School * Able to read and understand informed consent document * Patients presenting with a diagnosed need horizontal ridge augmentation with GBR without simultaneous implant placement, to allow for future dental implant placement. * Presence of periodontally healthy, non-carious neighboring teeth and/or healthy restored dental implants on either side of the edentulous span planned for GBR, or unhealthy adjacent teeth to be extracted during the same visit. * ≤4 mm ridge width in a Seibert Class I Edentulous span19 * No anticipated need for surgical and/or endodontic care at planned teeth adjacent to the proposed surgical site during the study period. Exclusion Criteria: * Non-English speaking * Less than 18 years old * Smokers/nicotine users (defined as currently reporting use of any form of tobacco/nicotine products) * Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing, including: * Uncontrolled diabetes (HbA1c \> 7%) * Untreated periodontal disease * History of head/neck radiation * IV bisphosphonates * Immunocompromised state * Pregnancy * Acute infection at site * Documented or suspected allergy or sensitivity to any study product

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acellular dermal matrix are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acellular dermal matrix Bone grafting Soft tissue grafting

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.